IRB #

STUDY00015619

Title

A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).

Principal Investigator

Laura Newell

Study Purpose

There are two purposes of this study. For the phase 1 portion of the study, it is to determine the optimal dose of the study drug (Vadastuximab Talirine). The purpose of the phase 2 portion of this study is to find out what effects, good and/or bad, the combination of regular chemotherapy plus the optimal dose of study drug has on you and your leukemia.

Medical Condition(s)

Myelodysplastic Syndrome (MDS)

Eligibility Criteria

Intermediate to high-risk MDS.
Age of at least 18.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Up to approximately 39 months.

Minors Included

No

Contact

Knight Clinical Trials Office Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Seattle Genetics

Recruitment End

05/15/2024

Compensation Provided

No


Go Back